CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Hipertensión arterial

Biblioteca de referencias

Detalles
G
ESPACIO de hipertensión arterial › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (4 anteriores a 1990, fuera del eje)

5101520212122454113323632104587661012518111619161319901995200020052010201520202025
286referencias: 226 artículos y guías, comprobados en PubMed y Crossref, y 54 fichas técnicas48de 2024, 2025 y 202633guías, consensos y declaraciones científicas

La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.

Descargar en RIS (286 referencias)

Artículos y guías en PubMed (225)

  1. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10(10):CD002252. doi:10.1002/14651858.CD002252.pub4 · PMID 30277556I1
  2. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85. doi:10.1056/NEJMoa1001286 · PMID 20228401C6G2
  3. Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110(9):2453-2495. doi:10.1210/clinem/dgaf284 · PMID 40658480H3
  4. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540-1550. doi:10.1016/S0140-6736(19)32135-X · PMID 31533906B7C6G2G5I1
  5. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021;385(27):2507-2519. doi:10.1056/NEJMoa2110730 · PMID 34739197C1C5C6G2I1
  6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97. doi:10.1001/jama.288.23.2981 · PMID 12479763C5G2I1
  7. Araujo-Castro M, Paja Fano M, González Boillos M, Pla Peris B, Pascual-Corrales E, García Cano AM, et al. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register). Endocrine. 2022;78(2):363-372. doi:10.1007/s12020-022-03122-8 · PMID 35751774H2
  8. Araujo-Castro M, Pascual-Corrales E, Martín Rojas P, Parra Ramírez P. Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry? Endocrine. 2024;83(3):527-536. doi:10.1007/s12020-023-03573-7 · PMID 37884825H2
  9. Araujo-Castro M, Ruiz-Sánchez JG, Parra Ramírez P, Martín Rojas-Marcos P, Aguilera-Saborido A, Gómez Cerezo JF, et al. Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 2024;85(1):99-121. doi:10.1007/s12020-024-03751-1 · PMID 38448679F1
  10. Araujo-Castro M, Ruiz-Sánchez JG, Ramírez PP, Martín Rojas-Marcos P, Aguilera-Saborido A, Gómez Cerezo JF, et al. Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document. Endocrine. 2024;85(2):532-544. doi:10.1007/s12020-024-03773-9 · PMID 38507182F1
  11. ASTRAL Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953-62. doi:10.1056/NEJMoa0905368 · PMID 19907042H3
  12. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-2345. doi:10.1016/S0140-6736(18)31082-1 · PMID 29803590G2I3
  13. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-2486. doi:10.1016/S0140-6736(21)00788-1 · PMID 34010611B7G2I3
  14. Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023;329(8):651-661. doi:10.1001/jama.2023.0713 · PMID 36853250B7G2I3
  15. Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988-999. doi:10.1016/S0140-6736(25)02549-8 · PMID 41794437D1G2G5H1
  16. Baena-Díez JM, Félix FJ, Grau M, Cabrera de León A, Sanz H, Leal M, et al. Tratamiento y control de los factores de riesgo según el riesgo coronario en la población española del estudio DARIOS. Rev Esp Cardiol. 2011;64(9):766-73. doi:10.1016/j.recesp.2011.04.019 · PMID 21764497G3
  17. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-36. doi:10.1001/jama.292.18.2227 · PMID 15536109I1
  18. Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740-749. doi:10.1001/jama.2024.0728 · PMID 38363577G2G5H1
  19. Banegas JR, Graciani A, de la Cruz-Troca JJ, León-Muñoz LM, Guallar-Castillón P, Coca A, et al. Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. Hypertension. 2012;60(4):898-905. doi:10.1161/HYPERTENSIONAHA.112.193078 · PMID 22949530G3H2
  20. Banegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J. 2014;35(46):3304-12. doi:10.1093/eurheartj/ehu016 · PMID 24497346G3H2
  21. Banegas JR, Sánchez-Martínez M, Gijón-Conde T, López-García E, Graciani A, Guallar-Castillón P, et al. Numerical values and impact of hypertension in Spain. Rev Esp Cardiol (Engl Ed). 2024;77(9):767-778. doi:10.1016/j.rec.2024.03.011 · PMID 38701882H2
  22. Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15):1313-1330. doi:10.1093/eurheartj/ehad054 · PMID 36790101I3
  23. Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002;11(2):95-100. doi:10.1080/08037050211265 · PMID 12035878I1
  24. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al. May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020;76(2):333-341. doi:10.1161/HYPERTENSIONAHA.120.14874 · PMID 32419505G3
  25. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369 · PMID 18378519G2I1
  26. Benetos A, Gautier S, Freminet A, Metz A, Labat C, Georgiopoulos I, et al. Reduction of Antihypertensive Treatment in Nursing Home Residents. N Engl J Med. 2025;393(20):1990-2000. doi:10.1056/NEJMoa2508157 · PMID 40879421C6G2
  27. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-401. doi:10.1056/NEJMoa1402670 · PMID 24678939G2I3
  28. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400(10361):1405-1416. doi:10.1016/S0140-6736(22)01787-1 · PMID 36130612I3
  29. Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155-1167. doi:10.1056/NEJMoa2412006 · PMID 39555827C6G2
  30. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-82. doi:10.1001/jama.289.16.2073 · PMID 12709465I1
  31. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0 · PMID 33933205G2
  32. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial. Circulation. 2021;144(15):1212-1226. doi:10.1161/CIRCULATIONAHA.121.055329 · PMID 34565172B7
  33. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486-92. doi:10.1038/ncpneph0575 · PMID 17717561G5H1
  34. Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. 2016;218:83-88. doi:10.1016/j.ijcard.2016.05.044 · PMID 27232917G3G5
  35. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9. doi:10.1056/NEJMoa011161 · PMID 11565518I1
  36. Bress AP, Anderson TS, Flack JM, Ghazi L, Hall ME, Laffer CL, et al. The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association. Hypertension. 2024;81(8):e94-e106. doi:10.1161/HYP.0000000000000238 · PMID 38804130B6H4
  37. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10-20. doi:10.7326/M20-0065 · PMID 32449886G3H2H3
  38. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-72. doi:10.1016/S0140-6736(00)02527-7 · PMID 10972368I1
  39. Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136-47. doi:10.1016/S2213-8587(15)00377-0 · PMID 26489809I1
  40. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. doi:10.1016/S0140-6736(20)30554-7 · PMID 32234534B7G2I3
  41. Böhm M, de la Sierra A, Mahfoud F, Schwantke I, Lauder L, Haring B, et al. Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes. Eur Heart J. 2024;45(31):2851-2861. doi:10.1093/eurheartj/ehae337 · PMID 38847237G3
  42. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.0000000000000084 · PMID 30354828B7
  43. Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National Rates of Nonadherence to Antihypertensive Medications Among Insured Adults With Hypertension, 2015. Hypertension. 2019;74(6):1324-1332. doi:10.1161/HYPERTENSIONAHA.119.13616 · PMID 31679429C8
  44. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42-8. doi:10.1161/CIRCULATIONAHA.107.737957 · PMID 18559700I1
  45. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559-569. doi:10.1016/j.kint.2020.10.026 · PMID 33637203C6G1
  46. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72. doi:10.1001/jama.289.19.2560 · PMID 12748199C7
  47. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-68. doi:10.1001/jama.2013.184182 · PMID 24002282G3
  48. Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043-1052. doi:10.1016/S0140-6736(21)01922-X · PMID 34469767G2
  49. Cinza-Sanjurjo S, Alonso-Moreno FJ, Prieto-Díaz MÁ, Divisón-Garrote JA, Rodríguez-Roca GC, Llisterri-Caro JL, et al. Hipertensión arterial resistente en pacientes hipertensos atendidos en Atención Primaria de España. Estudio PRESCAP 2010. Semergen. 2015;41(3):123-30. doi:10.1016/j.semerg.2014.02.014 · PMID 24768029G3H2
  50. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995. doi:10.1136/bmj.c3995 · PMID 20732968C8D4
  51. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9. doi:10.1016/s0140-6736(82)92202-4 · PMID 6121965I1
  52. Cohen JB, Byfield RL, Hardy ST, Juraschek SP, Houston Miller N, Mukkamala R, et al. Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association. Hypertension. 2026;83(3):e00254. doi:10.1161/HYP.0000000000000254 · PMID 41376592I3
  53. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysis. Curr Hypertens Rep. 2015;17(12):94. doi:10.1007/s11906-015-0606-5 · PMID 26560139C8
  54. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301 · PMID 2883575I1
  55. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13-22. doi:10.1056/NEJMoa1310753 · PMID 24245566H3
  56. Correction to: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. Eur Heart J. 2026;pii: ehag758. doi: 10.1093/eurheartj/ehag758. doi:10.1093/eurheartj/ehag758 · PMID 42708516G2
  57. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3 · PMID 11937178I1
  58. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1 · PMID 16154016G2I1
  59. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294I1
  60. de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 2009;53(3):466-72. doi:10.1161/HYPERTENSIONAHA.108.124008 · PMID 19171788G3
  61. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902. doi:10.1161/HYPERTENSIONAHA.110.168948 · PMID 21444835B7C4G3G5H2
  62. de la Sierra A, Vinyoles E, Banegas JR, Segura J, Gorostidi M, de la Cruz JJ, et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens. 2017;35(12):2388-2394. doi:10.1097/HJH.0000000000001493 · PMID 28723880H2
  63. de la Sierra A, Staplin N, Ruilope LM, Gorostidi M, Vinyoles E, Segura J, et al. A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality. J Hypertens. 2024;42(7):1197-1202. doi:10.1097/HJH.0000000000003712 · PMID 38477142G3
  64. de la Sierra A, Ruilope LM, Staplin N, Stergiou GS, Williams B. Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry. J Hypertens. 2025;43(4):642-648. doi:10.1097/HJH.0000000000003950 · PMID 39791439G3
  65. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389(3):228-238. doi:10.1056/NEJMoa2208391 · PMID 37467498G5
  66. Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, et al. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. JAMA. 2025;334(1):46-55. doi:10.1001/jama.2025.6681 · PMID 40434761G2G5
  67. Divisón Garrote JA, Grupo AMPA de la SEH-LELHA. Medidas domiciliarias de presión arterial. Documento de consenso. SEH-LELHA 2014. Hipertens Riesgo Vasc. 2015;32(1):27-39. doi:10.1016/j.hipert.2014.10.001 · PMID 26179855F1
  68. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921-6. doi:10.1016/S0140-6736(08)60834-X · PMID 18539224H3
  69. Durand H, Hayes P, Morrissey EC, Newell J, Casey M, Murphy AW, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346-2357. doi:10.1097/HJH.0000000000001502 · PMID 28777133C8
  70. Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, et al. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026;37(2):299-311. doi:10.1681/ASN.0000000849 · PMID 40913594G2G5
  71. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394(10203):1011-1021. doi:10.1016/S0140-6736(19)31282-6 · PMID 31378394I1
  72. Ehikioya E, Okobi OE, Beeko MAE, Abanga R, Abah NNI, Briggs L, et al. Comparing Intravenous Labetalol and Intravenous Hydralazine for Managing Severe Gestational Hypertension. Cureus. 2023;15(7):e42332. doi:10.7759/cureus.42332 · PMID 37614273I1
  73. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-7. doi:10.1016/S0140-6736(07)60108-1 · PMID 17240286C5
  74. Escobar C, Barrios V, Alonso-Moreno FJ, Prieto MA, Valls F, Calderon A, et al. Evolution of therapy inertia in primary care setting in Spain during 2002-2010. J Hypertens. 2014;32(5):1138-45; discussion 1145. doi:10.1097/HJH.0000000000000118 · PMID 24509126G3
  75. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967. doi:10.1016/S0140-6736(15)01225-8 · PMID 26724178C5
  76. Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 · PMID 40888730D1G2G5H1
  77. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. doi:10.1093/eurheartj/ehi115 · PMID 15642700I1
  78. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8. doi:10.1016/s0140-6736(03)14286-9 · PMID 13678872I1
  79. Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi:10.1056/NEJMoa2213169 · PMID 36342143G2G5H1
  80. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92(5):1326-31. doi:10.1161/01.cir.92.5.1326 · PMID 7648682I1
  81. Garrison SR, Bakal JA, Kolber MR, Korownyk CS, Green LA, Kirkwood JEM, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025;333(23):2061-2072. doi:10.1001/jama.2025.4390 · PMID 40354045C8G2
  82. Garrison SR, Youngson ERE, Perry DA, Campbell FN, Korownyk CS, Green LA, et al. Bedtime vs Morning Antihypertensive Medications in Frail Older Adults: The BedMed-Frail Randomized Clinical Trial. JAMA Netw Open. 2025;8(5):e2513812. doi:10.1001/jamanetworkopen.2025.13812 · PMID 40354050C8G2
  83. Gashaw IA, Tuttle KR, Monroy Kuhn M, Pleiner S, Delic D, Cronin L, et al. Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD. Eur J Endocrinol. 2026;194(1):46-57. doi:10.1093/ejendo/lvaf265 · PMID 41436034H1
  84. Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting. Rev Esp Cardiol (Engl Ed). 2014;67(4):270-6. doi:10.1016/j.rec.2013.09.027 · PMID 24774589B7H2
  85. Gijón-Conde T, Gorostidi M, Banegas JR, de la Sierra A, Segura J, Vinyoles E, et al. Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre monitorización ambulatoria de la presión arterial (MAPA) 2019. Hipertens Riesgo Vasc. 2019;36(4):199-212. doi:10.1016/j.hipert.2019.05.002 · PMID 31178410D4F1
  86. Gijón-Conde T, Rubio E, Gorostidi M, Vinyoles E, Armario P, Rodilla E, et al. 2021 Spanish Society of Hypertension position statement about telemedicine. Hipertens Riesgo Vasc. 2021;38(4):186-196. doi:10.1016/j.hipert.2021.03.003 · PMID 33888438F1
  87. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343(8906):1115-22. PMID 7910229I1
  88. Gorostidi M, Gijón-Conde T, de la Sierra A, Rodilla E, Rubio E, Vinyoles E, et al. Guía práctica sobre el diagnóstico y tratamiento de la hipertensión arterial en España, 2022. Sociedad Española de Hipertensión - Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). Hipertens Riesgo Vasc. 2022;39(4):174-194. doi:10.1016/j.hipert.2022.09.002 · PMID 36153303F1G1
  89. Grau M, Elosua R, Cabrera de León A, Guembe MJ, Baena-Díez JM, Vega Alonso T, et al. Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS. Rev Esp Cardiol. 2011;64(4):295-304. doi:10.1016/j.recesp.2010.11.005 · PMID 21397375G3
  90. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907-17. doi:10.1056/NEJMoa1007994 · PMID 21388309I1
  91. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C6
  92. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-65. doi:10.1016/s0140-6736(00)02526-5 · PMID 10972367I1
  93. He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401(10380):928-938. doi:10.1016/S0140-6736(22)02603-4 · PMID 36871573C8D4G2
  94. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-53. doi:10.1056/NEJM200001203420301 · PMID 10639539I1
  95. Hirschl MM, Seidler D, Zeiner A, Wagner A, Heinz G, Sterz F, et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med. 1993;11(6):653-6. doi:10.1016/0735-6757(93)90026-8 · PMID 8240575I1
  96. Hirschl MM, Binder M, Bur A, Herkner H, Müllner M, Woisetschläger C, et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med. 1997;23(8):885-8. doi:10.1007/s001340050426 · PMID 9310807I1
  97. Huang X, Xu N, Wang Y, Sun Y, Guo A. The effects of motivational interviewing on hypertension management: A systematic review and meta-analysis. Patient Educ Couns. 2023;112:107760. doi:10.1016/j.pec.2023.107760 · PMID 37075650C8
  98. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978-86. doi:10.1007/s00125-011-2325-z · PMID 21993710I1
  99. Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022;387(26):2401-2410. doi:10.1056/NEJMoa2212270 · PMID 36516076B7C5G2I1
  100. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182 · PMID 19052124G2I1
  101. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. doi:10.1001/jama.2013.284427 · PMID 24352797C7
  102. Jordan J, Biaggioni I, Kotsis V, Nilsson P, Grassi G, Fedorowski A, et al. Consensus statement on the definition of orthostatic hypertension endorsed by the American Autonomic Society and the Japanese Society of Hypertension. Clin Auton Res. 2023;33(1):69-73. doi:10.1007/s10286-022-00897-8 · PMID 36173501C7
  103. Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2025;40(6):1175-1186. doi:10.1093/ndt/gfae263 · PMID 39533115H1
  104. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. doi:10.1016/S0140-6736(04)16451-9 · PMID 15207952I1
  105. Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017;35(3):421-441. doi:10.1097/HJH.0000000000001197 · PMID 27977471D4
  106. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. doi:10.1016/S0140-6736(18)30951-6 · PMID 29803589B7G2I3
  107. Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023;82(19):1809-1823. doi:10.1016/j.jacc.2023.08.045 · PMID 37914510G2I3
  108. Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, et al. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. Circulation. 2024;149(24):1875-1884. doi:10.1161/CIRCULATIONAHA.124.069291 · PMID 38587557I3
  109. Kandzari DE, Mahfoud F, Townsend RR, Kario K, Weber MA, Schmieder RE, et al. Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED. J Am Heart Assoc. 2026;15(12):e049081. doi:10.1161/JAHA.126.049081 · PMID 42294771I3
  110. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 · PMID 37947085G1
  111. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 · PMID 33637192G1
  112. King JB, An J, Bellows BK, Cohen JB, Commodore-Mensah Y, Ghazi L, et al. Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2026;83(3):e00258. doi:10.1161/HYP.0000000000000258 · PMID 41392889C8
  113. Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. doi:10.1016/j.ejim.2024.05.033 · PMID 38914505G1
  114. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681-690. doi:10.1161/HYPERTENSIONAHA.117.10662 · PMID 29463627B7G2I1
  115. Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023;330(12):1140-1150. doi:10.1001/jama.2023.16029 · PMID 37690061G2G5
  116. Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025;392(18):1813-1823. doi:10.1056/NEJMoa2501440 · PMID 40267417G2G5
  117. Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025;333(23):2073-2082. doi:10.1001/jama.2025.5129 · PMID 40366680I1
  118. Legrand M, Falcone J, Cholley B, Charbonneau H, Delaporte A, Lemoine A, et al. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024;332(12):970-978. doi:10.1001/jama.2024.17123 · PMID 39212270C6
  119. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15(11):932-40. doi:10.1016/s0895-7061(02)03000-5 · PMID 12441211I1
  120. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. doi:10.1056/NEJMoa011303 · PMID 11565517I1
  121. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-86. doi:10.1097/00004872-200305000-00011 · PMID 12714861I1
  122. Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-255. doi:10.1016/S0140-6736(24)01028-6 · PMID 38945140G2
  123. Llisterri Caro JL, Rodríguez Roca GC, Alonso Moreno FJ, Prieto Díaz MA, Banegas Banegas JR, Gonzalez-Segura Alsina D, et al. Control de la presión arterial en la población hipertensa española asistida en Atención Primaria. Estudio PRESCAP 2010. Med Clin (Barc). 2012;139(15):653-61. doi:10.1016/j.medcli.2011.10.023 · PMID 22436384G3H2
  124. Llisterri JL, Rodriguez-Roca GC, Escobar C, Alonso-Moreno FJ, Prieto MA, Barrios V, et al. Treatment and blood pressure control in Spain during 2002-2010. J Hypertens. 2012;30(12):2425-31. doi:10.1097/HJH.0b013e3283592583 · PMID 22990354G3H2
  125. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2009-20. doi:10.1056/NEJMoa1600175 · PMID 27041480G2
  126. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005;23(3):641-8. doi:10.1097/01.hjh.0000160223.94220.29 · PMID 15716708I1
  127. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-1425. doi:10.1016/S0140-6736(22)01786-X · PMID 36240838C8G2
  128. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60. doi:10.1136/bmj.327.7421.955 · PMID 14576246I1
  129. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-17. doi:10.1056/NEJMoa1404595 · PMID 25629739C6I1
  130. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474-3482. doi:10.1093/eurheartj/ehz118 · PMID 30907413I3
  131. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401-1410. doi:10.1016/S0140-6736(22)00455-X · PMID 35390320I3
  132. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75. PMID 10789664I1
  133. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270-80. doi:10.1097/HJH.0b013e3283472643 · PMID 21558959I1
  134. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124(2):128-35. doi:10.1016/j.amjmed.2010.08.007 · PMID 21295192I1
  135. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009;31(8):1652-63. doi:10.1016/j.clinthera.2009.08.010 · PMID 19808126I1
  136. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480 · PMID 37345492C1C7G1
  137. Martell N, Rodriguez-Cerrillo M, Grobbee DE, López-Eady MD, Fernández-Pinilla C, Avila M, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press. 2003;12(3):149-54. doi:10.1080/08037050310009950 · PMID 12875476H2
  138. Maw AM, Thompson LE, Ho PM, Kennedy KF, Maddox TM, Valle JA, et al. Implications of Guideline Updates for the Management of Apparent Treatment Resistant Hypertension in the United States (A NCDR Research to Practice (R2P) Project). Am J Cardiol. 2020;125(1):63-67. doi:10.1016/j.amjcard.2019.09.033 · PMID 31727262G5
  139. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178 · PMID 39210715B6B7C1C4C5C6C7C8D1D3D4E3F1G1G2G3G5H1H3H4I1I3
  140. McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;346:f3030. doi:10.1136/bmj.f3030 · PMID 23709583C8
  141. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018;391(10124):949-959. doi:10.1016/S0140-6736(18)30309-X · PMID 29499873C8
  142. Menéndez E, Delgado E, Fernández-Vega F, Prieto MA, Bordiú E, Calle A, et al. Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl Ed). 2016;69(6):572-8. doi:10.1016/j.rec.2015.11.034 · PMID 26979767G3H2
  143. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-1820. doi:10.1016/j.jacc.2017.01.052 · PMID 28385310G3H2H3
  144. Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. Pregnancy Hypertens. 2022;29:1-6. doi:10.1016/j.preghy.2022.05.001 · PMID 35605426I1
  145. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. 2019;73(5):e35-e66. doi:10.1161/HYP.0000000000000087 · PMID 30827125D4I3
  146. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639-651. doi:10.1016/S0140-6736(19)31145-6 · PMID 31327564H2
  147. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1 · PMID 34450083G5
  148. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385(12):1067-1077. doi:10.1056/NEJMoa2105675 · PMID 34459569G2
  149. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105. doi:10.1136/heartjnl-2018-313599 · PMID 30087099B7G5
  150. Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. N Engl J Med. 2019;380(25):2429-2439. doi:10.1056/NEJMoa1901113 · PMID 30883050C5
  151. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317 · PMID 18378520C5G2I1
  152. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31(10):2094-102. doi:10.1097/HJH.0b013e3283638b1a · PMID 24107738I1
  153. Pallarés-Carratalá V, Ruiz-García A, Serrano-Cumplido A, Arranz-Martínez E, Divisón-Garrote JA, Moyá-Amengual A, et al. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study. Medicina (Kaunas). 2023;59(10). doi:10.3390/medicina59101846 · PMID 37893564G3
  154. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705. doi:10.1161/HYPERTENSIONAHA.120.15781 · PMID 33390044C8
  155. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980-90. doi:10.1097/HJH.0b013e3283455ca5 · PMID 21451421I1
  156. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-8. doi:10.1056/NEJMoa011489 · PMID 11565519I1
  157. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8 · PMID 17765963I1
  158. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108(9):710-7. PMID 8575241I1
  159. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-7. doi:10.1161/HYPERTENSIONAHA.111.179788 · PMID 21968750H3
  160. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. doi:10.1093/eurheartj/ehaa605 · PMID 32860412C6
  161. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-16. doi:10.1001/jama.290.21.2805 · PMID 14657064I1
  162. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. doi:10.1056/NEJMoa032292 · PMID 14610160I1
  163. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. doi:10.1056/NEJMoa030207 · PMID 12668699I1
  164. Polonia J, Martins L, Pinto F, Nazare J. Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study. J Hypertens. 2014;32(6):1211-21. doi:10.1097/HJH.0000000000000162 · PMID 24675681G3
  165. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7 · PMID 12853193I1
  166. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849-57. doi:10.1016/S0140-6736(04)16980-8 · PMID 15351192I1
  167. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64. PMID 2046107I1
  168. Prieto-Díaz MA, Pallares-Carratala V, Manuel Micó-Pérez R, Escobar-Cervantes C, Martín-Sanchez V, Coca A, et al. Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study. Front Cardiovasc Med. 2023;10:1295174. doi:10.3389/fcvm.2023.1295174 · PMID 38173815G3H2
  169. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5 · PMID 11589932I1
  170. Queiroga F, Araújo B, Rivera A, Consoli L, Ujjawal A, Mansouri ES, et al. Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials. JACC Adv. 2026;5(3):102621. doi:10.1016/j.jacadv.2026.102621 · PMID 41762177G2G5
  171. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857-63. PMID 9217756I1
  172. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976;2(7989):753-6. doi:10.1016/s0140-6736(76)90597-3 · PMID 61439I1
  173. Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. J Am Coll Cardiol. 2024;84(24):2393-2403. doi:10.1016/j.jacc.2024.08.025 · PMID 39217570G2
  174. Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404(10462):1536-1546. doi:10.1016/S0140-6736(24)01744-6 · PMID 39426836G2
  175. Rodilla E, Gorostidi M. Comment on the update of the 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension. Hipertens Riesgo Vasc. 2024;41(1):1-4. doi:10.1016/j.hipert.2024.02.004 · PMID 38431520F1
  176. Rodilla E, Benítez Camps M, Castilla Guerra L, Egocheaga Cabello MI, Gamarra Ortiz J, María Tablado MÁ, et al. Position paper on the 2024 ESH clinical practice guidelines for the management of arterial hypertension in Spain. Hipertens Riesgo Vasc. 2025;42(1):52-58. doi:10.1016/j.hipert.2024.09.003 · PMID 39567318F1G1
  177. Rodríguez-Marín D, Cruz J, Caballero FF, Graciani A, Rodríguez-Artalejo F, Banegas JR. Blood pressure below target levels in treated older patients with hypertension: prevalence and associated factors. Rev Esp Cardiol (Engl Ed). 2026;79(9):774-780. doi:10.1016/j.rec.2026.03.011 · PMID 42107758H2
  178. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. doi:10.1016/j.jacc.2006.07.059 · PMID 17161262H3
  179. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041-6. doi:10.1161/HYPERTENSIONAHA.114.05021 · PMID 25733245C5
  180. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101 · PMID 11136953G2
  181. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gąsecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021;6(2):XLVIII-LXXXIX. doi:10.1177/23969873211012133 · PMID 34780578C6
  182. Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025;334(5):409-418. doi:10.1001/jama.2025.9413 · PMID 40587141D1G2G5H1
  183. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-1937. doi:10.1016/S0140-6736(22)02034-7 · PMID 36356632G2G5H1I1
  184. Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study. Hypertension. 2023;80(5):1127-1135. doi:10.1161/HYPERTENSIONAHA.122.20810 · PMID 36987918C8
  185. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. doi:10.1093/eurheartj/ehab309 · PMID 34120177G1
  186. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-2467. doi:10.1093/eurheartj/ehab312 · PMID 34120185G1
  187. SEC Working Group for the 2024 ESC guidelines for the management elevated blood pressure and hypertension and SEC Guidelines Committee. Comments on the 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Rev Esp Cardiol (Engl Ed). 2025;78(4):296-300. doi:10.1016/j.rec.2024.11.018 · PMID 39922558F1
  188. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501 · PMID 2057034I1
  189. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685-91. doi:10.1056/NEJM199209033271003 · PMID 1463530I1
  190. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939 · PMID 26551272G2
  191. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021;384(20):1921-1930. doi:10.1056/NEJMoa1901281 · PMID 34010531G2
  192. SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507-15. doi:10.1016/S0140-6736(13)60852-1 · PMID 23726159C6G2
  193. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906-1916. doi:10.1111/bcp.13649 · PMID 29974489I1
  194. Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041-2050. doi:10.1016/S0140-6736(23)00733-X · PMID 37156250G3H2
  195. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al. A Universal Standard for the Validation of Blood Pressure Measuring Devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. Hypertension. 2018;71(3):368-374. doi:10.1161/HYPERTENSIONAHA.117.10237 · PMID 29386350I3
  196. Stergiou GS, O'Brien E, Myers M, Palatini P, Parati G, Kollias A, et al. STRIDE BP international initiative for accurate blood pressure measurement: Systematic review of published validation studies of blood pressure measuring devices. J Clin Hypertens (Greenwich). 2019;21(11):1616-1622. doi:10.1111/jch.13710 · PMID 31654494I3
  197. Stergiou GS, Palatini P, Parati G, O'Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302. doi:10.1097/HJH.0000000000002843 · PMID 33710173D4
  198. Stergiou GS, Avolio AP, Palatini P, Kyriakoulis KG, Schutte AE, Mieke S, et al. European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2023;41(12):2074-2087. doi:10.1097/HJH.0000000000003483 · PMID 37303198I3
  199. Sun G, Guo X, Zhao C, Ouyang N, Li G, Wang C, et al. Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial. Circulation. 2026;doi: 10.1161/CIRCULATIONAHA.126.082511. doi:10.1161/CIRCULATIONAHA.126.082511 · PMID 42666029C8G2
  200. Taddei S, Narkiewicz K, Bricout-Hennel S, Petrova P, Batailler C, Asmar R. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. Eur Heart J. 2026;pii: ehag022. doi: 10.1093/eurheartj/ehag022. doi:10.1093/eurheartj/ehag022 · PMID 41667119B7G2I1
  201. Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, et al. Eplerenone for hypertension. Cochrane Database Syst Rev. 2017;2(2):CD008996. doi:10.1002/14651858.CD008996.pub2 · PMID 28245343I1
  202. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-83. doi:10.1016/S0140-6736(08)61242-8 · PMID 18757085I1
  203. Theodorakopoulou M, Iatridi F, Theodosiadi A, Hecking M, Strippoli G, Sarafidis P. Efficacy and safety of selective aldosterone synthase inhibitors for blood pressure reduction in patients with CKD: a meta-analysis of randomized controlled trials. J Hypertens. 2026;44(10):1684-1691. doi:10.1097/HJH.0000000000004399 · PMID 42554270G5
  204. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. doi:10.1056/NEJMoa2201295 · PMID 35363951C6I1
  205. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61. doi:10.1136/heartjnl-2013-305063 · PMID 24694797C8
  206. Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379-390. doi:10.1016/S0140-6736(23)02408-X · PMID 38109916D1G2G5
  207. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225-30. doi:10.1016/j.amjcard.2012.09.020 · PMID 23111138I1
  208. Vallée A, Gabet A, Grave C, Sorbets E, Blacher J, Olié V. Patterns of hypertension management in France in 2015: The ESTEBAN survey. J Clin Hypertens (Greenwich). 2020;22(4):663-672. doi:10.1111/jch.13834 · PMID 32092238G3
  209. van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37-46. doi:10.1093/ehjcvp/pvy032 · PMID 30165588B6H4I1
  210. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088-97. doi:10.1093/eurheartj/ehs075 · PMID 22511654C5
  211. Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med. 2018;378(14):1291-1301. doi:10.1056/NEJMoa1717250 · PMID 29527973C8
  212. Vukadinović D, Lauder L, Kandzari DE, Bhatt DL, Kirtane AJ, Edelman ER, et al. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150(20):1599-1611. doi:10.1161/CIRCULATIONAHA.124.069709 · PMID 39355923I3
  213. Wacker JR, Wagner BK, Briese V, Schauf B, Heilmann L, Bartz C, et al. Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006;127(2):160-5. doi:10.1016/j.ejogrb.2005.09.013 · PMID 16253414I1
  214. Weir MR, Bhaduri S, Lee K, Galvez O, Kooienga L, Kopjar B, et al. Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. Kidney Int. 2026;pii: S0085-2538(26)00808-2. doi: 10.1016/j.kint.2026.08.021. doi:10.1016/j.kint.2026.08.021 · PMID 42778148G2G5
  215. White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, et al. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). Circulation. 2019;140(20):1626-1635. doi:10.1161/CIRCULATIONAHA.119.041603 · PMID 31607143G2
  216. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259(13):1976-82. PMID 3346979I1
  217. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3 · PMID 26414968B7C5G2G5H1I1
  218. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464-475. doi:10.1016/S2213-8587(18)30071-8 · PMID 29655877G2H1I1
  219. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583-92. doi:10.1056/NEJMoa021716 · PMID 12584366I1
  220. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1(1):CD002003. doi:10.1002/14651858.CD002003.pub5 · PMID 28107561C5I1
  221. Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114-e218. doi:10.1161/CIR.0000000000001356 · PMID 40811497B6C1C7C8D4G1H3H4
  222. Wu HZ, Cheng Y, Yu D, Li JB, Jiang YF, Zhu ZN. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. Hypertens Pregnancy. 2022;41(2):126-138. doi:10.1080/10641955.2022.2056196 · PMID 35361052I1
  223. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41. doi:10.1053/j.ajkd.2015.10.011 · PMID 26597926C5
  224. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492 · PMID 21073363I1
  225. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-1279. doi:10.1056/NEJMoa2111437 · PMID 34491661C6G2

Otros documentos con DOI (1)

  1. THEACUTEINFARCTIONRAMIPRILEFFI. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Lancet. 1993;342(8875). doi:10.1016/0140-6736(93)92693-NI1

Fichas técnicas (CIMA, AEMPS) (54)

  1. Ficha técnica de aliskireno. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 07405022I2
  2. Ficha técnica de amilorida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 53265I1I2
  3. Ficha técnica de amlodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59162C5I1I2
  4. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 55529C5I2
  5. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 57655C5I1I2
  6. Ficha técnica de candesartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61894I1I2
  7. Ficha técnica de captopril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 62318I2
  8. Ficha técnica de carvedilol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59695C5I1I2
  9. Ficha técnica de clonidina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 50669I2
  10. Ficha técnica de clortalidona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 45843C1C5I1I2
  11. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 60217I2
  12. Ficha técnica de doxazosina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 62655I1I2
  13. Ficha técnica de enalapril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 57789C1C5I1I2
  14. Ficha técnica de eplerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 66756C1C5I2
  15. Ficha técnica de espironolactona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 54900C1C5I2
  16. Ficha técnica de felodipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 64832I2
  17. Ficha técnica de finerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1211616002I2
  18. Ficha técnica de hidroclorotiazida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 90834C1C5I1I2
  19. Ficha técnica de indapamida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 53338C5I2
  20. Ficha técnica de irbesartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 97046022I1I2
  21. Ficha técnica de labetalol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 54527C1
  22. Ficha técnica de labetalol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 55318I1
  23. Ficha técnica de lacidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59897I2
  24. Ficha técnica de lercanidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 71633I1I2
  25. Ficha técnica de losartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 64971C1C5I1I2
  26. Ficha técnica de manidipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 64634I2
  27. Ficha técnica de metildopa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 37932I1I2
  28. Ficha técnica de moxonidina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61156I2
  29. Ficha técnica de nebivolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 83604C5I2
  30. Ficha técnica de nifedipino. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59538C1C5I1I2
  31. Ficha técnica de olmesartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 65498I1I2
  32. Ficha técnica de prazosina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 55064I2
  33. Ficha técnica de ramipril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59564C1C5I1I2
  34. Ficha técnica de registro 39059. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 39059I1
  35. Ficha técnica de registro 54503. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 54503C5I1
  36. Ficha técnica de registro 55285. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 55285I1
  37. Ficha técnica de registro 56967. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 56967I1
  38. Ficha técnica de registro 58369. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 58369C5I1I2
  39. Ficha técnica de registro 58860. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 58860I1
  40. Ficha técnica de registro 59127. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59127I1I2
  41. Ficha técnica de registro 59911. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59911I1
  42. Ficha técnica de registro 60200. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 60200C5I1
  43. Ficha técnica de registro 61252. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61252I1
  44. Ficha técnica de registro 61369. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61369I1
  45. Ficha técnica de registro 61428. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61428I1
  46. Ficha técnica de registro 66356. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 66356I1
  47. Ficha técnica de registro 68827. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 68827I1I2
  48. Ficha técnica de registro 79824. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 79824I1
  49. Ficha técnica de registro 81034. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 81034C1
  50. Ficha técnica de registro 85873. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 85873I1
  51. Ficha técnica de registro 89082. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 89082I1
  52. Ficha técnica de telmisartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 98090002I1I2
  53. Ficha técnica de urapidilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 76741I1
  54. Ficha técnica de valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 70323C1C5I1I2

Estudios en marcha (ClinicalTrials.gov) (6)

  1. EMBRACE. Denervación renal en pacientes con enfermedad coronaria multivaso e hipertensión resistente a los que se hace una intervención coronaria en dos tiempos; objetivo principal, una variable combinada jerarquizada (razón de victorias), con la seguridad del acceso, el daño renal por contraste y las complicaciones de la arteria renal. ClinicalTrials.gov, NCT07602790; 1.000 pacientes · aleatorizado; aún sin reclutar · resultados primarios previstos: noviembre de 2030 · promotor: industria. Consultado el 25/10/2026. NCT07602790I3
  2. RADAR. Inyección de alcohol frente a procedimiento simulado, sin fármacos; la sistólica ambulatoria a las 8 semanas. ClinicalTrials.gov, NCT07083765; 202 pacientes · aleatorizado; aún sin reclutar · resultados primarios previstos: mayo de 2028 · promotor: industria. Consultado el 25/10/2026. NCT07083765I3
  3. RDN-ADPKD. Denervación renal en la hipertensión no controlada con poliquistosis renal autosómica dominante; la sistólica de 24 horas. ClinicalTrials.gov, NCT05460169; 44 pacientes · aleatorizado; activo, sin reclutar · resultados primarios previstos: marzo de 2028 · promotor: Universidad de Erlangen-Núremberg. Consultado el 25/10/2026. NCT05460169I3
  4. RDN-DA. La duración de cada aplicación de radiofrecuencia y su efecto sobre la presión, en la hipertensión y la hipertensión resistente; la sistólica de 24 horas a los 6 meses. ClinicalTrials.gov, NCT07876479; 220 pacientes · aleatorizado; reclutando · resultados primarios previstos: diciembre de 2028 · promotor: Hospital Ruijin, Shanghái. Consultado el 25/10/2026. NCT07876479I3
  5. REDs. Denervación renal en la fase subaguda del ictus; la sistólica de 24 horas a los 12 meses. ClinicalTrials.gov, NCT07114757; 108 pacientes · aleatorizado; aún sin reclutar · resultados primarios previstos: septiembre de 2027 · promotor: Centro per la Lotta Contro l'Infarto, Italia. Consultado el 25/10/2026. NCT07114757I3
  6. WHY-RDN. Denervación renal o arteriografía sola en mujeres hipertensas que planean un embarazo; la normalización de la presión de 24 horas. ClinicalTrials.gov, NCT05563337; 80 pacientes · aleatorizado; reclutando · resultados primarios previstos: mayo de 2025, fecha ya pasada; el registro lo sigue dando como abierto · promotor: Hospital Universitario de Burdeos. Consultado el 25/10/2026. NCT05563337I3
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los estudios en marcha, en ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.